Nevertheless, monoclonal antibodies have been in clinics as targeted cancer therapy (e.g., Avastin (bevacizumab, anti-angiogenic)) and Herceptin (trastuzumab, anti-HER2 receptor in HER2-positive breast cancers) [100], and, therefore, anti-Gal1 mAbs research should be encouraged with an aim for inclusion in future clinical studies. Here, LGALS1 is linked to breast carcinoma.